Hold off investments: company postponing future planned investment/development/marketing while continuing substantive business

Stay Pausing Investments

Novo Nordisk is a Danish pharmaceutical company.

 
 
 
 
 

Hold off investments: company postponing future planned investment/development/marketing while continuing substantive business

Stay Pausing Investments
Revenue(RF), mln.USD
146
Assets(RF), mln.USD
156
Capital(RF), mln.USD
122
Glob.Revenue, mln.USD
33709
Staff(RF), 2021
635
Taxes(RF), mln.USD
16

Danish diabetes care giant Novo Nordisk has announced it is terminating supplies of its Ozempic (semaglutide) to Russia at the end of the current year.

The Company Statement
May 23, 2023

Suspend further marketing and clinical investment; pause new clinical trials and active enrollment but increased revenue in Russia in 2022 vs 2021. Danish diabetes care giant Novo Nordisk (NOV: N) has announced it is terminating supplies of its Ozempic (semaglutide) to Russia at the end of year 2024.

Open the Statement
Statements Archive
February 18, 2025The copycat brands that are replacing Ozempic in Russia
December 26, 2024Russians spent almost 6 billion rubles on generics of ozempic
November 19, 2024PSK Pharma received government permission to produce an analogue of Ozempic
December 15, 2023An analogue of Ozempic went on sale despite the patent
October 06, 2023The first analogue of a drug for glucose control has been registered in Russia
March 29, 2022https://www.novonordisk.com/news-and-media/critical-updates.html
March 29, 2022Novo Nordisk to stop supplies of diabetes drug Ozempic to Russia this year
Demand to Leave Russia:Petition text has been copied to the clipboard.
Share the Company Status:
All company names used on this web page are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
Company statements and statistical data are collected from open sources and official registers according to the methodology of the KSE Institute.
Scanner